The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones
NEW YORK , July 31, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shares of Bausch Health Companies Inc. (BHC) declined 6.3% after the company reported mixed results for the second quarter of 2025.Adjusted earnings per share of 90 cents missed the Zacks Consensus Estimate...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DURECT Corporation (NASDAQ: DRRX) to Bausch Health Companies Inc. for $1.75 per share is fair to DURECT shareholders....
The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health . Click ...
LAVAL, QC and CUPERTINO, Calif. , July 29, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation...